Cumberland Pharmaceuticals Inc.

254 articles about Cumberland Pharmaceuticals Inc.

• Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update

  11/9/2021

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, is providing a company update and third quarter 2021 financial results.

• Cumberland Pharmaceuticals To Announce Third Quarter 2021 Financial Results

  11/2/2021

  Cumberland Pharmaceuticals Inc. announced that it will release third quarter 2021 financial results and provide a Company update after the market closes on Tuesday, November 9, 2021.

• Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis

  9/29/2021

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the national launch of its RediTrex® line of pre-filled syringes designed for the safe and simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.

• Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update

  8/10/2021

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, is providing a company update and second quarter 2021 financial results.

• Cumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results

  8/3/2021

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2021 financial results and provide a Company update after the market closes on Tuesday, August 10, 2021

• Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020

  7/26/2021

  Cumberland Pharmaceuticals Inc. today released its 2020 Sustainability Report, which details the company's activities pertaining to environmental, social and governance (ESG) matters.

• Vibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients

  6/21/2021

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, released a series of case reports describing the effectiveness of Vibativ® in treating secondary bacterial infections in COVID-19 patients – particularly those with other significant health problems, such as obesity, diabetes and heart disease.

• Cumberland Pharmaceuticals Names John Hamm New Chief Financial Officer

  5/19/2021

   Cumberland Pharmaceuticals Inc.   (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it has promoted John Hamm to   Director Finance & Accounting and Chief Financial Officer .

• Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update

  5/11/2021

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, is providing a company update and first quarter 2021 financial results.

• Cumberland Pharmaceuticals To Announce First Quarter 2021 Financial Results

  5/4/2021

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2021 financial results and Company update after the market closes on Tuesday, May 11, 2021.

• Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020

  3/9/2021

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results. Net Revenues for the fourth quarter were $10.3 million , up 10% over the prior year period.

• Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results

  3/2/2021

   Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update after the market closes on Tuesday, Mar. 9, 2021 . A conference call and live internet webcast will be held on Tuesday, March 9, 2021 , at 4:30 p.m. Eastern Time

• Introducing RediTrex®, A New Methotrexate Delivery System

  11/17/2020

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) injection.

• Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update

  11/10/2020

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million . The company also recorded an additional $750,000 in revenue during the third quarter

• Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use

  8/18/2020

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical Therapeutics.

• Cumberland Pharmaceuticals Reports Second Quarter 2020 Financial Results & Company Update

  8/11/2020

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology, provided a company update and announced second quarter 2020 financial results.

• Cumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results

  8/4/2020

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2020 financial results and Company update after the market closes on Tuesday, Aug. 11, 2020.

• Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients

  7/20/2020

   Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a Level 1 Trauma Center study recently published in the Journal of Orthopedic Trauma. Results demon

• New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis

  5/26/2020

  Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis.

• Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update

  5/20/2020

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a company update and announced first quarter 2020 financial results